Optimal group testing strategy for the mass screening of SARS-CoV-2
•Two aspects of group testing efficiency are analyzed, one concerning the maximization of the welfare throughput and the other concerning the maximization of the identification rate.•To ensure the test effectiveness, both the group size and the prevalence of SARS-CoV- 2 must be below certain respect...
Saved in:
| Published in | Omega (Oxford) Vol. 112; p. 102689 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.10.2022
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | •Two aspects of group testing efficiency are analyzed, one concerning the maximization of the welfare throughput and the other concerning the maximization of the identification rate.•To ensure the test effectiveness, both the group size and the prevalence of SARS-CoV- 2 must be below certain respective thresholds.•The optimal group size is jointly determined by the test accuracy parameters, the infection prevalence rate, and the relative importance of identifying infected subjects.•The optimal group size that maximizes the welfare throughput is weakly smaller than the one that maximizes the identification rate.
We analyze the group testing strategy that maximizes the efficiency of the SARS-CoV-2 screening test while ensuring its effectiveness, where the effectiveness of group testing guarantees that negative results from pooled samples can be considered presumptive negative. Two aspects of test efficiency are considered, one concerning the maximization of the welfare throughput and the other concerning the maximization of the identification rate (namely, identifying as many infected individuals as possible). We show that compared with individual testing, group testing leads to a higher probability of false negative results but a lower probability of false positive results. To ensure the test effectiveness, both the group size and the prevalence of SARS-CoV-2 must be below certain respective thresholds. To achieve test efficiency that concerns either the welfare throughput maximization or the identification rate maximization, the optimal group size is jointly determined by the test accuracy parameters, the infection prevalence rate, and the relative importance of identifying infected subjects. We also show that the optimal group size that maximizes the welfare throughput is weakly smaller than the one that maximizes the identification rate. |
|---|---|
| AbstractList | We analyze the group testing strategy that maximizes the efficiency of the SARS-CoV-2 screening test while ensuring its effectiveness, where the effectiveness of group testing guarantees that negative results from pooled samples can be considered presumptive negative. Two aspects of test efficiency are considered, one concerning the maximization of the welfare throughput and the other concerning the maximization of the identification rate (namely, identifying as many infected individuals as possible). We show that compared with individual testing, group testing leads to a higher probability of false negative results but a lower probability of false positive results. To ensure the test effectiveness, both the group size and the prevalence of SARS-CoV-2 must be below certain respective thresholds. To achieve test efficiency that concerns either the welfare throughput maximization or the identification rate maximization, the optimal group size is jointly determined by the test accuracy parameters, the infection prevalence rate, and the relative importance of identifying infected subjects. We also show that the optimal group size that maximizes the welfare throughput is weakly smaller than the one that maximizes the identification rate.We analyze the group testing strategy that maximizes the efficiency of the SARS-CoV-2 screening test while ensuring its effectiveness, where the effectiveness of group testing guarantees that negative results from pooled samples can be considered presumptive negative. Two aspects of test efficiency are considered, one concerning the maximization of the welfare throughput and the other concerning the maximization of the identification rate (namely, identifying as many infected individuals as possible). We show that compared with individual testing, group testing leads to a higher probability of false negative results but a lower probability of false positive results. To ensure the test effectiveness, both the group size and the prevalence of SARS-CoV-2 must be below certain respective thresholds. To achieve test efficiency that concerns either the welfare throughput maximization or the identification rate maximization, the optimal group size is jointly determined by the test accuracy parameters, the infection prevalence rate, and the relative importance of identifying infected subjects. We also show that the optimal group size that maximizes the welfare throughput is weakly smaller than the one that maximizes the identification rate. We analyze the group testing strategy that maximizes the efficiency of the SARS-CoV-2 screening test while ensuring its effectiveness, where the effectiveness of group testing guarantees that negative results from pooled samples can be considered presumptive negative. Two aspects of test efficiency are considered, one concerning the maximization of the welfare throughput and the other concerning the maximization of the identification rate (namely, identifying as many infected individuals as possible). We show that compared with individual testing, group testing leads to a higher probability of false negative results but a lower probability of false positive results. To ensure the test effectiveness, both the group size and the prevalence of SARS-CoV-2 must be below certain respective thresholds. To achieve test efficiency that concerns either the welfare throughput maximization or the identification rate maximization, the optimal group size is jointly determined by the test accuracy parameters, the infection prevalence rate, and the relative importance of identifying infected subjects. We also show that the optimal group size that maximizes the welfare throughput is weakly smaller than the one that maximizes the identification rate. •Two aspects of group testing efficiency are analyzed, one concerning the maximization of the welfare throughput and the other concerning the maximization of the identification rate.•To ensure the test effectiveness, both the group size and the prevalence of SARS-CoV- 2 must be below certain respective thresholds.•The optimal group size is jointly determined by the test accuracy parameters, the infection prevalence rate, and the relative importance of identifying infected subjects.•The optimal group size that maximizes the welfare throughput is weakly smaller than the one that maximizes the identification rate. We analyze the group testing strategy that maximizes the efficiency of the SARS-CoV-2 screening test while ensuring its effectiveness, where the effectiveness of group testing guarantees that negative results from pooled samples can be considered presumptive negative. Two aspects of test efficiency are considered, one concerning the maximization of the welfare throughput and the other concerning the maximization of the identification rate (namely, identifying as many infected individuals as possible). We show that compared with individual testing, group testing leads to a higher probability of false negative results but a lower probability of false positive results. To ensure the test effectiveness, both the group size and the prevalence of SARS-CoV-2 must be below certain respective thresholds. To achieve test efficiency that concerns either the welfare throughput maximization or the identification rate maximization, the optimal group size is jointly determined by the test accuracy parameters, the infection prevalence rate, and the relative importance of identifying infected subjects. We also show that the optimal group size that maximizes the welfare throughput is weakly smaller than the one that maximizes the identification rate. |
| ArticleNumber | 102689 |
| Author | Wang, Yulan Guo, Pengfei Huang, Fengfeng |
| Author_xml | – sequence: 1 givenname: Fengfeng orcidid: 0000-0001-5756-7348 surname: Huang fullname: Huang, Fengfeng email: ffhuang@uestc.edu.cn organization: School of Management and Economics, University of Electronic Science and Technology of China, China – sequence: 2 givenname: Pengfei surname: Guo fullname: Guo, Pengfei email: penguo@cityu.edu.hk organization: College of Business, City University of Hong Kong, Kowloon, Hong Kong – sequence: 3 givenname: Yulan orcidid: 0000-0003-4184-590X surname: Wang fullname: Wang, Yulan email: yulan.wang@polyu.edu.hk organization: Faculty of Business, The Hong Kong Polytechnic University, Kowloon, Hong Kong |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35637769$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUctKJDEUDUPL9GP8AkFqOZtq86hUJQsHpNGZAUHwMduQTt0q01RV2iQt9N-bnlZRF7q5F-495z7OmaLR4AZA6IjgOcGkPFnNXQ-tnlNMaarQUshvaEJExXJOq2KEJphhnuNCsDGahrDCGBOB2Xc0ZrxkVVXKCVpcraPtdZe13m3WWYQQ7dBmIXodod1mjfNZvIes1yFkwXiAYdd3TXZzdn2TL9y_nP5AB43uAhw-5xm6uzi_XfzJL69-_12cXeam4DLmtayYgGZZYGmKgklumJCCA6s5IxiWRlPOgQpZlaWWJdAlEYzUtakFkcAEm6Ff-7nrzbKH2sCQruzU2qcH_FY5bdX7zmDvVeselSS04EmXGfr5PMC7h016VfU2GOg6PYDbBEXLijJaiRRn6PjtrtclL8olANsDjHcheGheIQSrnT9qpf77o3b-qL0_iSU_sIyNOlq3O9h2X3BP91xIGj9a8CoYC4OB2nowUdXOfsp_AhhYq54 |
| CitedBy_id | crossref_primary_10_37394_23209_2023_20_47 crossref_primary_10_37394_23206_2024_23_28 crossref_primary_10_1016_j_omega_2023_102912 crossref_primary_10_3390_healthcare11030393 |
| Cites_doi | 10.1093/biomet/82.2.287 10.1016/S1473-3099(20)30362-5 10.1002/sim.4780132205 10.1287/mnsc.1120.1576 10.1561/0100000099 10.15585/mmwr.mm6524e2 10.1016/S0001-2998(78)80014-2 10.1186/1471-2334-10-82 10.1038/s41586-020-2279-8 10.1214/aoms/1177731363 10.1007/978-3-642-36899-8_31 10.1002/(SICI)1097-0258(19980715)17:13<1447::AID-SIM862>3.0.CO;2-K 10.1126/sciadv.abc5961 10.1111/poms.13606 10.1287/mnsc.1100.1236 10.1287/mnsc.2018.3138 10.1128/JCM.00522-10 10.1001/jama.288.2.216 |
| ContentType | Journal Article |
| Copyright | 2022 Elsevier Ltd 2022 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd |
| Copyright_xml | – notice: 2022 Elsevier Ltd – notice: 2022 Elsevier Ltd. All rights reserved. – notice: 2022 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd |
| DBID | AAYXX CITATION NPM 7X8 5PM |
| DOI | 10.1016/j.omega.2022.102689 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Business |
| EISSN | 1873-5274 0305-0483 |
| EndPage | 102689 |
| ExternalDocumentID | PMC9124587 35637769 10_1016_j_omega_2022_102689 S0305048322000962 |
| Genre | Journal Article |
| GroupedDBID | --K --M -~X .~1 0R~ 13V 1B1 1OL 1RT 1~. 1~5 29N 4.4 457 4G. 5VS 7-5 71M 8P~ 96U 9JO AAAKF AAAKG AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARIN AAXUO ABJNI ABKBG ABMAC ABMVD ABUCO ABXDB ABYKQ ACBMB ACDAQ ACGFS ACHQT ACHRH ACNCT ACNTT ACRLP ADBBV ADEZE ADIYS ADMUD AEBSH AEKER AENEX AFACB AFAZI AFFNX AFKWA AFTJW AGHFR AGJBL AGQRV AGUBO AGUMN AGYEJ AHEHV AHHHB AHMBA AIEXJ AIKHN AITUG AJBFU AJOXV ALEQD ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ APLSM ASPBG AVWKF AXJTR AZFZN BAAKF BDEBP BKOJK BKOMP BLXMC BNSAS CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q G8K GBLVA HAMUX HVGLF HZ~ IAO IEA IGG IHE IHR IOF IPO ITC J1W KOM LPU LXL LY1 M41 MO0 MS~ N95 O-L O9- OAUVE OHT OZT P-8 P-9 PC. PQQKQ Q38 R2- RIG ROL RPZ SDF SDG SDP SDS SES SEW SPCBC SSB SSD SSL SSZ T5K TAE TAF TN5 U5U VQA WUQ XI7 XPP XSW XYO YNT ZRQ ~G- AATTM AAXKI AAYWO AAYXX ABDPE ABWVN ACRPL ACVFH ADCNI ADMHG ADNMO ADVLN AEIPS AEUPX AFJKZ AFPUW AFXIZ AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP BNPGV CITATION IPC SSH EFKBS NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c459t-d9738efb409c44395c38985e3d5310ebca255e289766a96e2b1831ddcd819e383 |
| IEDL.DBID | .~1 |
| ISSN | 0305-0483 |
| IngestDate | Thu Aug 21 18:28:25 EDT 2025 Fri Jul 11 01:18:09 EDT 2025 Mon Jul 21 05:59:27 EDT 2025 Tue Jul 01 02:57:32 EDT 2025 Thu Apr 24 22:58:51 EDT 2025 Fri Feb 23 02:40:48 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Test specificity Group testing Mass screening Test sensitivity |
| Language | English |
| License | 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c459t-d9738efb409c44395c38985e3d5310ebca255e289766a96e2b1831ddcd819e383 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-5756-7348 0000-0003-4184-590X |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC9124587 |
| PMID | 35637769 |
| PQID | 2672327872 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9124587 proquest_miscellaneous_2672327872 pubmed_primary_35637769 crossref_primary_10_1016_j_omega_2022_102689 crossref_citationtrail_10_1016_j_omega_2022_102689 elsevier_sciencedirect_doi_10_1016_j_omega_2022_102689 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-10-01 |
| PublicationDateYYYYMMDD | 2022-10-01 |
| PublicationDate_xml | – month: 10 year: 2022 text: 2022-10-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Omega (Oxford) |
| PublicationTitleAlternate | Omega |
| PublicationYear | 2022 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| References | Pilcher, McPherson, Leone, Smurzynski, Owen-O’Dowd, Peace-Brewer (bib0020) 2002; 288 Aldridge, Johnson, Scarlett (bib0002) 2019; 15 Dorfman (bib0007) 1943; 14 Aprahamian, Bish, Bish (bib0004) 2019; 65 Metz (bib0016) 1978; 8 Lohse, Pfuhl, Berko-Gottel, Rissland, Geibler, Gartner (bib0013) 2020 Malyutov (bib0014) 2013 Ackerman, Myhrvold, Thakku, Freije, Metsky, Yang, Ye, Boehm, Kosoko-Thoroddsen, Kehe, Nguyen (bib0001) 2020; 582 on March 7, 2022. Zenios, Wein (bib0028) 1998; 17 Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, Hasell J, Macdonald B, Beltekian D, Roser M. Coronavirus pandemic (COVID-19). 2022. Published online at Phatarfod, Sudbury (bib0019) 1994; 13 Huang, Guo, Wang (bib0009) 2022; 31 Hsiang, Lin, Dokomajilar, Kemere, Pilcher, Dorsey (bib0010) 2010; 48 Mentus, Romeo, DiPaola (bib0015) 2020 Schneider M. COVID-19 single-stage pooled testing method approved in israel. 2020. Lin Y, Ren Y, Wan J, Zhou E. Group testing during the COVID-19 pandemic: optimal group size selection and prevalence control. 2020. arXiv Cowling, Lau, Wu, Wong, Fang, Riley (bib0006) 2010; 10 Retrieved from . Wang, Debo, Scheller-Wolf, Smith (bib0025) 2010; 11 Bastos, Tavaziva, Abidi, Campbell, Haraoui, Johnston (bib0005) 2020; 370 Healthcare in Europe. Corona ‘pool testing’ increases worldwide capacities many times over. 2020. United State Food and Drug Administration, Drug. Does FDA have validation or other recommendations regarding SARS-cov-2 diagnostic/screening tests for use with sample pooling?2020. Alizamir, De Vericourt, Sun (bib0003) 2013; 1 Tu, Litvak, Pagano (bib0022) 1995; 82 New York State. Governor cuomo announces new testing initiatives to improve COVID-19 detection & control across new york state. 2020. Walden M, Zhao I. How china managed to test almost 1.5m people for coronavirus in a single day. 2020. Shental, Levy, Wuvshet, Skorniakov, Shalem, Ottolenghi, Greenshpan, Steinberg, Edri, Gillis, Goldhirsh (bib0027) 2020; 6 Wilson JMG, Jungner G. World Health Organization. Principles and practice of screening for disease. 1968. Kuehnert MJ. Screening of blood donations for zika virus infection—puerto rico, april 3 june 11, 2016. MMWR. morbidity and mortality weekly report, 65. 2016. Mentus (10.1016/j.omega.2022.102689_bib0015) 2020 Aldridge (10.1016/j.omega.2022.102689_bib0002) 2019; 15 Bastos (10.1016/j.omega.2022.102689_bib0005) 2020; 370 Wang (10.1016/j.omega.2022.102689_bib0025) 2010; 11 Phatarfod (10.1016/j.omega.2022.102689_bib0019) 1994; 13 Alizamir (10.1016/j.omega.2022.102689_bib0003) 2013; 1 Tu (10.1016/j.omega.2022.102689_bib0022) 1995; 82 Pilcher (10.1016/j.omega.2022.102689_bib0020) 2002; 288 10.1016/j.omega.2022.102689_bib0012 Lohse (10.1016/j.omega.2022.102689_bib0013) 2020 10.1016/j.omega.2022.102689_bib0011 Aprahamian (10.1016/j.omega.2022.102689_bib0004) 2019; 65 10.1016/j.omega.2022.102689_bib0018 Huang (10.1016/j.omega.2022.102689_bib0009) 2022; 31 Hsiang (10.1016/j.omega.2022.102689_bib0010) 2010; 48 10.1016/j.omega.2022.102689_bib0017 Malyutov (10.1016/j.omega.2022.102689_sbref0014) 2013 Zenios (10.1016/j.omega.2022.102689_bib0028) 1998; 17 Metz (10.1016/j.omega.2022.102689_sbref0016) 1978; 8 Shental (10.1016/j.omega.2022.102689_sbref0027) 2020; 6 10.1016/j.omega.2022.102689_bib0026 10.1016/j.omega.2022.102689_bib0023 10.1016/j.omega.2022.102689_bib0024 10.1016/j.omega.2022.102689_bib0021 Dorfman (10.1016/j.omega.2022.102689_bib0007) 1943; 14 Ackerman (10.1016/j.omega.2022.102689_bib0001) 2020; 582 Cowling (10.1016/j.omega.2022.102689_bib0006) 2010; 10 10.1016/j.omega.2022.102689_bib0008 |
| References_xml | – reference: Wilson JMG, Jungner G. World Health Organization. Principles and practice of screening for disease. 1968. – volume: 1 start-page: 157 year: 2013 end-page: 171 ident: bib0003 article-title: Diagnosis accuracy under congestion publication-title: Manage Sci – volume: 288 start-page: 216 year: 2002 end-page: 221 ident: bib0020 article-title: Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population publication-title: JAMA – reference: New York State. Governor cuomo announces new testing initiatives to improve COVID-19 detection & control across new york state. 2020. – reference: Kuehnert MJ. Screening of blood donations for zika virus infection—puerto rico, april 3 june 11, 2016. MMWR. morbidity and mortality weekly report, 65. 2016. – volume: 17 start-page: 1447 year: 1998 end-page: 1467 ident: bib0028 article-title: Pooled testing for hiv prevalence estimation: exploiting the dilution effect publication-title: Stat Med – volume: 31 start-page: 1216 year: 2022 end-page: 1234 ident: bib0009 article-title: Modeling patients’ illness perception and equilibrium analysis of their doctor shopping behavior publication-title: Product Oper Manage – volume: 11 start-page: 1873 year: 2010 end-page: 1890 ident: bib0025 article-title: Design and analysis of diagnostic service centers publication-title: Manage Sci – reference: Walden M, Zhao I. How china managed to test almost 1.5m people for coronavirus in a single day. 2020. – volume: 82 start-page: 287 year: 1995 end-page: 297 ident: bib0022 article-title: On the informativeness and accuracy of pooled testing in estimating prevalence of a rare disease: application to HIV screening publication-title: Biometrika – reference: . Retrieved from: – year: 2013 ident: bib0014 article-title: Search for sparse active inputs: a review publication-title: Information theory, combinatorics, and search theory: in memory of rudolf ahlswede – volume: 15 start-page: 196 year: 2019 end-page: 392 ident: bib0002 article-title: Group testing: an information theory perspective publication-title: Found Trend Commun Inform Theory – volume: 6 year: 2020 ident: bib0027 article-title: Efficient high-throughput SARS-cov-2 testing to detect asymptomatic carriers publication-title: Sci Adv – volume: 48 start-page: 3539 year: 2010 end-page: 3543 ident: bib0010 article-title: PCR-Based pooling of dried blood spots for detection of malaria parasites: optimization and application to a cohort of ugandan children publication-title: J Clin Microbiol – volume: 14 start-page: 436 year: 1943 end-page: 440 ident: bib0007 article-title: The detection of defective members of large populations publication-title: Ann Math Stat – year: 2020 ident: bib0015 article-title: Analysis and applications of adaptive group testing methods for COVID-19 publication-title: MedRxiv – reference: Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, Hasell J, Macdonald B, Beltekian D, Roser M. Coronavirus pandemic (COVID-19). 2022. Published online at – reference: . – reference: Lin Y, Ren Y, Wan J, Zhou E. Group testing during the COVID-19 pandemic: optimal group size selection and prevalence control. 2020. arXiv: – reference: Healthcare in Europe. Corona ‘pool testing’ increases worldwide capacities many times over. 2020. – reference: Schneider M. COVID-19 single-stage pooled testing method approved in israel. 2020. – volume: 370 year: 2020 ident: bib0005 article-title: Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis publication-title: BMJ – reference: on March 7, 2022. – volume: 65 start-page: 4365 year: 2019 end-page: 4384 ident: bib0004 article-title: Optimal risk-based group testing publication-title: Manage Sci – reference: United State Food and Drug Administration, Drug. Does FDA have validation or other recommendations regarding SARS-cov-2 diagnostic/screening tests for use with sample pooling?2020. – volume: 8 start-page: 283 year: 1978 end-page: 298 ident: bib0016 article-title: Basic principles of ROC analysis publication-title: Semin Nucl Med – volume: 582 start-page: 277 year: 2020 end-page: 282 ident: bib0001 article-title: Massively multiplexed nucleic acid detection with cas13 publication-title: Nature – volume: 10 start-page: 1 year: 2010 end-page: 4 ident: bib0006 article-title: Entry screening to delay local transmission of 2009 pandemic influenza a (h1n1) publication-title: BMC Infect Dis – volume: 13 start-page: 2337 year: 1994 end-page: 2343 ident: bib0019 article-title: The use of a square array scheme in blood testing publication-title: Stat Med – year: 2020 ident: bib0013 article-title: Pooling of samples for testing for SARS-cov-2 in asymptomatic people publication-title: Lancet Infect Dis – ident: 10.1016/j.omega.2022.102689_bib0026 – volume: 82 start-page: 287 year: 1995 ident: 10.1016/j.omega.2022.102689_bib0022 article-title: On the informativeness and accuracy of pooled testing in estimating prevalence of a rare disease: application to HIV screening publication-title: Biometrika doi: 10.1093/biomet/82.2.287 – year: 2020 ident: 10.1016/j.omega.2022.102689_bib0013 article-title: Pooling of samples for testing for SARS-cov-2 in asymptomatic people publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(20)30362-5 – volume: 13 start-page: 2337 issue: 22 year: 1994 ident: 10.1016/j.omega.2022.102689_bib0019 article-title: The use of a square array scheme in blood testing publication-title: Stat Med doi: 10.1002/sim.4780132205 – volume: 1 start-page: 157 issue: 59 year: 2013 ident: 10.1016/j.omega.2022.102689_bib0003 article-title: Diagnosis accuracy under congestion publication-title: Manage Sci doi: 10.1287/mnsc.1120.1576 – volume: 15 start-page: 196 issue: 3–4 year: 2019 ident: 10.1016/j.omega.2022.102689_bib0002 article-title: Group testing: an information theory perspective publication-title: Found Trend Commun Inform Theory doi: 10.1561/0100000099 – ident: 10.1016/j.omega.2022.102689_bib0011 doi: 10.15585/mmwr.mm6524e2 – volume: 8 start-page: 283 issue: 4 year: 1978 ident: 10.1016/j.omega.2022.102689_sbref0016 article-title: Basic principles of ROC analysis publication-title: Semin Nucl Med doi: 10.1016/S0001-2998(78)80014-2 – volume: 370 year: 2020 ident: 10.1016/j.omega.2022.102689_bib0005 article-title: Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis publication-title: BMJ – volume: 10 start-page: 1 issue: 1 year: 2010 ident: 10.1016/j.omega.2022.102689_bib0006 article-title: Entry screening to delay local transmission of 2009 pandemic influenza a (h1n1) publication-title: BMC Infect Dis doi: 10.1186/1471-2334-10-82 – ident: 10.1016/j.omega.2022.102689_bib0017 – volume: 582 start-page: 277 issue: 7811 year: 2020 ident: 10.1016/j.omega.2022.102689_bib0001 article-title: Massively multiplexed nucleic acid detection with cas13 publication-title: Nature doi: 10.1038/s41586-020-2279-8 – volume: 14 start-page: 436 issue: 4 year: 1943 ident: 10.1016/j.omega.2022.102689_bib0007 article-title: The detection of defective members of large populations publication-title: Ann Math Stat doi: 10.1214/aoms/1177731363 – year: 2013 ident: 10.1016/j.omega.2022.102689_sbref0014 article-title: Search for sparse active inputs: a review doi: 10.1007/978-3-642-36899-8_31 – ident: 10.1016/j.omega.2022.102689_bib0024 – volume: 17 start-page: 1447 issue: 13 year: 1998 ident: 10.1016/j.omega.2022.102689_bib0028 article-title: Pooled testing for hiv prevalence estimation: exploiting the dilution effect publication-title: Stat Med doi: 10.1002/(SICI)1097-0258(19980715)17:13<1447::AID-SIM862>3.0.CO;2-K – ident: 10.1016/j.omega.2022.102689_bib0012 – year: 2020 ident: 10.1016/j.omega.2022.102689_bib0015 article-title: Analysis and applications of adaptive group testing methods for COVID-19 publication-title: MedRxiv – volume: 6 issue: 37 year: 2020 ident: 10.1016/j.omega.2022.102689_sbref0027 article-title: Efficient high-throughput SARS-cov-2 testing to detect asymptomatic carriers publication-title: Sci Adv doi: 10.1126/sciadv.abc5961 – volume: 31 start-page: 1216 issue: 3 year: 2022 ident: 10.1016/j.omega.2022.102689_bib0009 article-title: Modeling patients’ illness perception and equilibrium analysis of their doctor shopping behavior publication-title: Product Oper Manage doi: 10.1111/poms.13606 – volume: 11 start-page: 1873 issue: 56 year: 2010 ident: 10.1016/j.omega.2022.102689_bib0025 article-title: Design and analysis of diagnostic service centers publication-title: Manage Sci doi: 10.1287/mnsc.1100.1236 – volume: 65 start-page: 4365 issue: 9 year: 2019 ident: 10.1016/j.omega.2022.102689_bib0004 article-title: Optimal risk-based group testing publication-title: Manage Sci doi: 10.1287/mnsc.2018.3138 – volume: 48 start-page: 3539 issue: 10 year: 2010 ident: 10.1016/j.omega.2022.102689_bib0010 article-title: PCR-Based pooling of dried blood spots for detection of malaria parasites: optimization and application to a cohort of ugandan children publication-title: J Clin Microbiol doi: 10.1128/JCM.00522-10 – ident: 10.1016/j.omega.2022.102689_bib0018 – volume: 288 start-page: 216 issue: 2 year: 2002 ident: 10.1016/j.omega.2022.102689_bib0020 article-title: Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population publication-title: JAMA doi: 10.1001/jama.288.2.216 – ident: 10.1016/j.omega.2022.102689_bib0021 – ident: 10.1016/j.omega.2022.102689_bib0008 – ident: 10.1016/j.omega.2022.102689_bib0023 |
| SSID | ssj0001803 |
| Score | 2.3845935 |
| Snippet | •Two aspects of group testing efficiency are analyzed, one concerning the maximization of the welfare throughput and the other concerning the maximization of... We analyze the group testing strategy that maximizes the efficiency of the SARS-CoV-2 screening test while ensuring its effectiveness, where the effectiveness... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 102689 |
| SubjectTerms | Group testing Mass screening Test sensitivity Test specificity |
| Title | Optimal group testing strategy for the mass screening of SARS-CoV-2 |
| URI | https://dx.doi.org/10.1016/j.omega.2022.102689 https://www.ncbi.nlm.nih.gov/pubmed/35637769 https://www.proquest.com/docview/2672327872 https://pubmed.ncbi.nlm.nih.gov/PMC9124587 |
| Volume | 112 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSwMxEA6iIF7Et_VFBI_GbrPZZHMsRamKClbFW2g2Wa3YXdF68OJvd2Yf1ap48LibBMJMMvmGfPmGkD0dOtf3wjOeBooJG4bMRlqzKOHWORWkvhCePzuX3WtxchvdTpFO_RYGaZVV7C9jehGtqz_NyprNp8Gg2cOlioLonBdAHOOwEApX-cH7J82jFQdliWQkqUHvWnmo4HjlQ3-H4kOco4SBxFrvv59OP9HndxLll1PpaIHMV3CStssZL5Ipny2R2ZrNvkw6FxAShtCjeL1BR6ipkd3Rl1KT9o0CZKUAAekQMDSFCAJZLbbnKe21L3usk98wvkKujw6vOl1W1U1giYj0iDmtwtinFlK3RADgiBJAJXHkQwcbLkD2E-QRHjItJWVfS88t7OuWc4kDeOAhZV0l01me-XVCU6XjVFvbgmQT70DjtA85jG05L0IRB75BeG0vk1Si4ljb4tHU7LEHUxjZoJFNaeQG2R8Peio1Nf7uLmtHmImlYSDq_z1wt3abgU2DNyH9zOevL4ZLBUgSYhVvkLXSjeOZhJEMlZIwWk04eNwBBbknW7LBfSHMrQEsRbHa-O-EN8kcfpVcwS0yPXp-9duAeUZ2p1jUO2SmfXzaPf8A6KH_jA |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LaxsxEB6CA20voe86fanQY4XX2pW0OhrT4NSOC7VdfBPWSpu4xLshcQ79953Zh6nb4kOvKw2IGenTN-zoG4CPJvZ-FZLARR5pnrg45k4aw2UmnPc6ykMlPH8xVaNF8mUpl0cwbN_CUFllg_01pldo3XzpNd7s3azXvRltVRJEF6Ii4ojDx6ROJTtwPDgfj6Y7QO6nUd0lmerU0KAVH6rKvMpNuCT9ISFIxUBRu_d_X1B_E9A_6yh_u5jOHsNJwyjZoF70EzgKxVN40Ba0P4PhV0SFDc6oHnCwLclqFJfsrpal_cmQtTJkgWyDNJohiGBiS-NlzmaDbzM-LL9z8RwWZ5_nwxFvWifwLJFmy73RcRpyh9lbliDnkBkSk1SG2OOZi6gAClOJgMmWVmplVBAOj3bf-8wjQwiYtb6ATlEW4RWwXJs0N871Md-k36BpvsI0xvV9SOIkjUIXROsvmzW64tTe4tq2BWQ_bOVkS062tZO78GlndFPLahyertpA2L3dYRH4Dxt-aMNm8dzQz5BVEcr7OyuURjKJcCW68LIO424lsVSx1gqt9V6AdxNIk3t_pFhfVdrcBvmSTPXp_y74PTwczS8mdnI-Hb-GRzRSlw6-gc729j68RQq0de-aLf4Lqb8CTA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Optimal+group+testing+strategy+for+the+mass+screening+of+SARS-CoV-2&rft.jtitle=Omega+%28Oxford%29&rft.au=Huang%2C+Fengfeng&rft.au=Guo%2C+Pengfei&rft.au=Wang%2C+Yulan&rft.date=2022-10-01&rft.pub=Elsevier+Ltd&rft.issn=0305-0483&rft.eissn=1873-5274&rft.volume=112&rft_id=info:doi/10.1016%2Fj.omega.2022.102689&rft.externalDocID=S0305048322000962 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0305-0483&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0305-0483&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0305-0483&client=summon |